Thermo Fisher Scientific (NYSE:TMO) PT Lowered to $620.00 at Robert W. Baird

Thermo Fisher Scientific (NYSE:TMO) had its target price lowered by Robert W. Baird from $621.00 to $620.00 in a report published on Thursday morning, Benzinga reports. Robert W. Baird currently has an outperform rating on the medical research company’s stock.

TMO has been the subject of several other reports. Sanford C. Bernstein restated a market perform rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. Citigroup initiated coverage on shares of Thermo Fisher Scientific in a research report on Monday, March 18th. They issued a neutral rating and a $620.00 price target on the stock. Evercore ISI raised their price target on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an outperform rating in a research report on Thursday, April 4th. Raymond James raised their price target on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an outperform rating in a research report on Thursday, February 1st. Finally, The Goldman Sachs Group raised their price target on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a buy rating in a research report on Wednesday, April 10th. Five research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of Moderate Buy and a consensus price target of $606.76.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock opened at $573.60 on Thursday. The company has a current ratio of 1.70, a quick ratio of 1.39 and a debt-to-equity ratio of 0.68. The business has a 50-day moving average price of $573.60 and a two-hundred day moving average price of $530.14. Thermo Fisher Scientific has a 1-year low of $415.60 and a 1-year high of $603.82. The company has a market cap of $218.95 billion, a P/E ratio of 36.79, a PEG ratio of 2.42 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, beating the consensus estimate of $4.70 by $0.41. The company had revenue of $10.35 billion during the quarter, compared to the consensus estimate of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. As a group, analysts anticipate that Thermo Fisher Scientific will post 21.56 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were paid a dividend of $0.39 per share. The ex-dividend date was Thursday, March 14th. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.01%.

Insider Transactions at Thermo Fisher Scientific

In other news, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the completion of the sale, the director now owns 1,207 shares in the company, valued at approximately $660,192.79. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, Director Debora L. Spar sold 164 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the transaction, the director now directly owns 1,207 shares in the company, valued at approximately $660,192.79. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the completion of the transaction, the chief executive officer now owns 49,155 shares of the company’s stock, valued at $27,311,992.65. The disclosure for this sale can be found here. Insiders sold a total of 50,277 shares of company stock worth $28,513,384 in the last quarter. Insiders own 0.32% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. WCM Investment Management LLC grew its position in shares of Thermo Fisher Scientific by 0.3% during the 4th quarter. WCM Investment Management LLC now owns 989,837 shares of the medical research company’s stock valued at $527,524,000 after purchasing an additional 2,928 shares in the last quarter. Phoenix Holdings Ltd. grew its position in shares of Thermo Fisher Scientific by 21.4% during the 3rd quarter. Phoenix Holdings Ltd. now owns 9,366 shares of the medical research company’s stock valued at $4,750,000 after purchasing an additional 1,654 shares in the last quarter. DMC Group LLC grew its position in shares of Thermo Fisher Scientific by 16.5% during the 3rd quarter. DMC Group LLC now owns 592 shares of the medical research company’s stock valued at $300,000 after purchasing an additional 84 shares in the last quarter. S. R. Schill & Associates grew its position in shares of Thermo Fisher Scientific by 106.3% during the 4th quarter. S. R. Schill & Associates now owns 1,537 shares of the medical research company’s stock valued at $816,000 after purchasing an additional 792 shares in the last quarter. Finally, Check Capital Management Inc. CA purchased a new position in shares of Thermo Fisher Scientific during the 3rd quarter valued at $219,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.